Heartburn: Labs, Diagnosis, and Next Steps

Why Heartburn Happens: The Physiology Behind the Burn

Heartburn results from gastric acid contacting the esophageal squamous epithelium, which lacks the protective mucus barrier of gastric mucosa. The lower esophageal sphincter (LES) normally prevents this contact. Transient LES relaxations (TLESRs), not simply a "weak" sphincter, account for up to 70% of reflux episodes in patients with GERD [1].

Several anatomical and functional factors increase TLESR frequency. A hiatal hernia displaces the gastroesophageal junction above the diaphragmatic crura, eliminating the external compression that reinforces the LES. In a prospective study of 590 patients undergoing endoscopy, hiatal hernia was present in 94% of those with severe erosive esophagitis compared to 29% of controls [2]. Obesity compounds this: each 5-unit increase in body mass index raises GERD risk by approximately 1.5-fold, likely through elevated intra-abdominal pressure [3].

Diet plays a role, but not in the way most patients assume. Coffee, chocolate, and spicy food receive disproportionate blame. A 2006 Stanford systematic review found that only weight loss and head-of-bed elevation had consistent evidence supporting symptom improvement; eliminating specific foods had minimal effect in controlled trials [4]. The physiology matters here because treatment decisions hinge on whether the problem is excess acid production, impaired clearance, or hypersensitive esophageal mucosa. These are distinct mechanisms requiring different interventions.

The Clinical History: What Your Doctor Listens For

A focused history remains the most cost-effective diagnostic step. The American College of Gastroenterology (ACG) 2022 guidelines state that "a presumptive diagnosis of GERD can be established in the setting of typical symptoms of heartburn and regurgitation" [5]. No lab or imaging study is required for uncomplicated cases in patients under 60.

Clinicians listen for alarm features. Dysphagia (difficulty swallowing), odynophagia (painful swallowing), unintended weight loss exceeding 5% of body weight, persistent vomiting, and gastrointestinal bleeding each warrant prompt investigation. These symptoms shift the pretest probability away from benign reflux and toward esophageal stricture, malignancy, or eosinophilic esophagitis (EoE).

Symptom timing also matters. Nocturnal heartburn correlates with more severe mucosal damage. A large cross-sectional survey (N=11,685) published in the American Journal of Gastroenterology found that 74% of patients with nighttime GERD reported impaired next-day function, and these patients had higher rates of erosive disease on endoscopy [6]. Asking about positional triggers, meal timing, and medication use (NSAIDs, bisphosphonates, doxycycline) can reveal modifiable causes that resolve without acid suppression at all.

The Empiric PPI Trial: First-Line Diagnostic and Treatment

For patients with typical symptoms and no alarm features, guidelines recommend starting a standard-dose PPI for 8 weeks. This approach functions simultaneously as a diagnostic test and a treatment. If heartburn resolves, the clinical diagnosis of GERD is confirmed. If symptoms persist, further workup is needed.

PPIs inhibit the hydrogen-potassium ATPase pump on parietal cells. A Cochrane meta-analysis of 134 trials found that PPIs healed erosive esophagitis in 83% of patients at 8 weeks, compared to 52% for histamine-2 receptor antagonists (H2RAs) and 28% for placebo [7]. Standard doses include omeprazole 20 mg, lansoprazole 30 mg, esomeprazole 20 mg, or pantoprazole 40 mg daily, taken 30-60 minutes before the first meal.

The "PPI test" has a sensitivity of approximately 78% and specificity of 54% for GERD diagnosis [8]. This imperfect specificity explains why some patients improve on PPIs for reasons unrelated to acid reflux. Functional heartburn and esophageal hypersensitivity can show partial PPI response through placebo effect or mild acid component. Clinicians who understand these limitations avoid indefinite empiric therapy when the diagnosis remains uncertain after the initial trial.

Short courses carry minimal risk. Concerns about long-term PPI use (fracture risk, kidney disease, dementia) apply to chronic therapy measured in years, not an 8-week diagnostic trial. The ACG guidelines note that "the benefits of PPIs in appropriate GERD patients outweigh potential risks" [5].

When Labs Enter the Picture

Heartburn itself does not require blood work. But certain clinical scenarios call for targeted laboratory evaluation.

Complete blood count (CBC). Iron-deficiency anemia in a patient with chronic heartburn raises concern for occult blood loss from erosive esophagitis, Cameron lesions within a hiatal hernia, or rarely, esophageal or gastric malignancy. A ferritin level below 30 ng/mL alongside a low mean corpuscular volume (MCV) warrants endoscopic evaluation regardless of symptom severity [9].

H. pylori testing. The relationship between Helicobacter pylori and GERD is complex. H. pylori infection actually decreases GERD risk in some populations by reducing gastric acid output. The ACG does not recommend routine H. pylori testing solely for heartburn. Testing becomes appropriate when patients have concurrent dyspepsia, a history of peptic ulcer disease, or when long-term PPI therapy is planned, because PPI use can produce false-negative urea breath test results [10].

Serum gastrin. Fasting gastrin levels are not part of a standard heartburn workup. They become relevant when patients fail to respond to high-dose PPI therapy, raising concern for Zollinger-Ellison syndrome (gastrinoma). A fasting gastrin level exceeding 1,000 pg/mL strongly suggests gastrinoma, though PPIs themselves can raise gastrin to 2-3 times the upper limit of normal [11].

Thyroid function. Hypothyroidism slows esophageal motility and may exacerbate reflux symptoms. Checking TSH is reasonable in patients with refractory heartburn and other signs of thyroid dysfunction (fatigue, weight gain, constipation) but is not a routine GERD lab.

Eosinophil markers. Peripheral eosinophilia can suggest EoE, a condition that mimics GERD in up to 8% of PPI-refractory patients. A study in Clinical Gastroenterology and Hepatology (N=261) found that 40% of patients with EoE had peripheral eosinophil counts above 500 cells/mcL [12]. Tissue biopsy during endoscopy remains the definitive test, but an elevated peripheral count adds pre-test suspicion.

Upper Endoscopy: Who Needs It and What It Shows

Upper endoscopy (esophagogastroduodenoscopy, or EGD) directly visualizes the esophageal mucosa and allows tissue sampling. Not every patient with heartburn needs one. The ACG recommends endoscopy for patients with alarm symptoms, those who fail an 8-week PPI trial, and those with risk factors for Barrett esophagus (GERD symptoms exceeding 5 years, male sex, age over 50, obesity, tobacco use, Caucasian ethnicity, family history of Barrett or esophageal adenocarcinoma) [5].

The Los Angeles classification grades erosive esophagitis from A through D. Grade A involves mucosal breaks under 5 mm, while Grade D involves circumferential mucosal damage. Grades C and D are considered conclusive for GERD. A prospective multicenter study found that 30% of GERD patients had erosive findings, while 70% had a normal-appearing esophagus on endoscopy, a condition termed non-erosive reflux disease (NERD) [13].

Biopsies serve two purposes. In the distal esophagus, salmon-colored mucosal changes suggest Barrett esophagus (intestinal metaplasia), which carries an annual esophageal adenocarcinoma risk of 0.5% per year [14]. The AGA recommends surveillance endoscopy every 3-5 years for non-dysplastic Barrett segments. Biopsies also detect EoE when ≥15 eosinophils per high-power field are present in the squamous epithelium.

Dr. Stuart Spechler, a gastroenterologist at UT Southwestern and a leading Barrett esophagus researcher, has stated: "The goal of Barrett surveillance is not to find cancer. It is to find dysplasia, the precursor, while intervention is still curative" [14]. This framing helps patients understand why surveillance endoscopy exists even when they feel well.

Ambulatory Reflux Monitoring: The Gold Standard

When endoscopy is normal and symptoms persist despite PPI therapy, ambulatory reflux monitoring becomes the definitive test. Two modalities exist.

Wireless pH capsule (Bravo). A small capsule is attached to the esophageal wall during endoscopy and transmits pH data wirelessly for 48-96 hours. An acid exposure time (AET) exceeding 6% of total recording time is abnormal. This test is performed off PPI therapy (after a 7-day washout) when the question is "does this patient have GERD at all?"

pH-impedance monitoring. A transnasal catheter measures both acid and non-acid reflux events over 24 hours. The Lyon Consensus 2.0 (2024) established updated thresholds: AET above 6% is conclusively abnormal, AET below 4% is conclusively normal, and values between 4-6% are inconclusive and require adjunctive measures such as total reflux episodes (abnormal if exceeding 80 in 24 hours) and mean nocturnal baseline impedance (abnormal if below 1,500 ohms) [15].

Dr. C. Prakash Gyawali, professor of gastroenterology at Washington University in St. Louis and lead author of the Lyon Consensus, explains: "The updated criteria address the gray zone that previously left 20-30% of patients without a definitive diagnosis. Adding impedance metrics alongside pH data allows clinicians to classify these borderline cases with greater confidence" [15].

This test matters because it separates patients into actionable categories. Those with proven pathologic reflux may benefit from surgical fundoplication or magnetic sphincter augmentation. Those with normal reflux exposure likely have functional heartburn or esophageal hypersensitivity, conditions better treated with neuromodulators (tricyclic antidepressants, SSRIs) than with stronger acid suppression.

Esophageal Manometry: Ruling Out Motility Disorders

High-resolution manometry (HRM) measures the pressure dynamics of esophageal peristalsis and LES function. It is not a test for GERD per se but is required before any antireflux surgery and helps identify motility disorders that masquerade as refractory heartburn.

Achalasia, a condition where the LES fails to relax properly, can produce heartburn-like chest symptoms and regurgitation. The Chicago Classification v4.0 categorizes esophageal motility into normal, ineffective esophageal motility (IEM), absent contractility, distal esophageal spasm, hypercontractile esophagus (jackhammer esophagus), and three subtypes of achalasia [16]. Identifying these patterns changes management entirely. A patient with achalasia treated with PPIs will not improve. They need pneumatic dilation, peroral endoscopic myotomy (POEM), or Heller myotomy.

IEM deserves specific mention. Found in roughly 20-30% of patients with refractory GERD, IEM indicates weak peristalsis that impairs esophageal acid clearance. For these patients, a Nissen (360-degree) fundoplication is avoided in favor of a partial (Toupet, 270-degree) wrap to reduce the risk of post-surgical dysphagia [17].

Treatment Pathways After Diagnosis

Treatment follows a stepwise algorithm based on findings from the workup outlined above.

Confirmed erosive esophagitis (LA Grade A-D). Standard-dose PPI for 8 weeks, then step down to the lowest effective dose. Grades C and D require maintenance PPI therapy because relapse rates exceed 80% within 6 months of discontinuation [5]. A repeat endoscopy at 8-12 weeks confirms mucosal healing.

NERD with proven acid exposure. Start with standard-dose PPI. If partial response, consider twice-daily dosing or switching PPI formulation. Potassium-competitive acid blockers (P-CABs) such as vonoprazan 20 mg daily represent a newer option. The phase 3 PHALCON-EE trial (N=1,024) demonstrated vonoprazan's non-inferiority to lansoprazole for erosive esophagitis healing at 8 weeks, with superior healing rates for severe (LA Grade C/D) disease: 92.9% vs. 86.5% [18].

Functional heartburn (normal acid exposure, normal endoscopy). Neuromodulators are first-line. Low-dose amitriptyline (10-25 mg nightly) or nortriptyline reduced heartburn symptom scores by 51% compared to 26% with placebo in a randomized trial of 75 patients [19]. Cognitive behavioral therapy and esophageal-directed hypnotherapy show emerging evidence in this subgroup.

Barrett esophagus without dysplasia. Continue PPI therapy (which may reduce dysplasia progression), initiate surveillance endoscopy per AGA intervals, and optimize modifiable risk factors. Weight loss of 10% or more has been associated with regression of Barrett segment length in observational data.

Eosinophilic esophagitis. PPI therapy is now considered first-line for EoE (reclassified from an exclusion criterion to a treatment). Dupilumab (Dupixent) 300 mg weekly received FDA approval for EoE in 2022 after a phase 3 trial showed histologic remission in 60% of patients versus 5% with placebo [20].

Lifestyle Modifications With Actual Evidence

Not all lifestyle advice carries equal weight. Evidence supports these interventions specifically.

Weight loss reduces reflux burden. A prospective cohort study of 332 patients found that a BMI reduction of 3.5 units or more decreased reflux symptom scores by 75% and normalized esophageal acid exposure in 65% of participants [21]. This effect rivals that of PPI therapy in overweight patients with moderate symptoms.

Left-lateral decubitus positioning during sleep. The stomach's greater curvature sits inferiorly in this position, keeping the gastroesophageal junction above the acid pool. A crossover trial showed a 67% reduction in total acid exposure time with left-side sleeping versus right-side or supine positioning [22].

Head-of-bed elevation (6-8 inches). Gravity-assisted esophageal clearance. A randomized trial demonstrated a significant reduction in esophageal acid contact time with bed elevation compared to flat positioning [4].

Meal timing matters for nocturnal symptoms. Eating within 3 hours of bedtime increases nocturnal acid exposure. The effect is most pronounced for high-fat meals, which delay gastric emptying and increase TLESR frequency.

Tobacco cessation reduces TLESR frequency within days of quitting. Alcohol, particularly wine and spirits above 5% ABV, directly damages esophageal mucosa and relaxes the LES. Both warrant specific clinical advice.

When Surgery Becomes the Right Answer

Antireflux surgery is appropriate for patients with objectively confirmed GERD (abnormal pH study) who cannot tolerate long-term PPI therapy, prefer not to take daily medication, or have large-volume regurgitation that PPIs do not address (PPIs reduce acid, not reflux volume).

Laparoscopic Nissen fundoplication remains the most studied procedure. A 5-year follow-up of the LOTUS trial (N=554) comparing esomeprazole to laparoscopic fundoplication found similar remission rates: 92% surgical vs. 95% medical [23]. The surgical group, however, had fewer regurgitation symptoms and used no daily medication.

The LINX magnetic sphincter augmentation device offers a less invasive alternative. A 5-year prospective study (N=100) showed that 85% of LINX patients discontinued daily PPI use, and median esophageal acid exposure normalized from 11.9% to 3.1% [24]. LINX is contraindicated in patients with Barrett esophagus, severe esophagitis, or hiatal hernias exceeding 3 cm.

Transoral incisionless fundoplication (TIF) is a fully endoscopic option for patients with small hiatal hernias and moderate GERD. Outcomes data beyond 5 years remain limited, and the procedure is less effective than laparoscopic fundoplication for severe disease.